The debate over the commercialization of human biological materials always comes back to one fundamental point: like it or not, we live in a market-driven society, and science is part of that market. Baruch Blumberg, the Nobel Prize-winning researcher who used Ted Slavin’s antibodies for hepatitis B research, told me, “Whether you think the commercialization of medical research is good or bad depends on how into capitalism you are.”
